Burden of illness of neovascular age-related macular degeneration in Canada

Canadian Journal of Ophthalmology

Volumn 42, Issue 6, 2007, Pages 836-843

  Cruess, Alan ^a   Zlateva, Gergana ^b   Xu, Xiao ^c   Rochon, Sophie ^b,d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b PFIZER INC   (United States)

^c Covance Market Access Services Inc   (United States)

^d Pfizer Canada Inc ^*  (Canada)

Author keywords

Health care resource utilization; Quality of life; Visual acuity

Indexed keywords

ADL DISABILITY; ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; COST OF ILLNESS; DEPRESSION; FALLING; FEMALE; FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; QUESTIONNAIRE; RETINA MACULA AGE RELATED DEGENERATION; SELF REPORT; WELLBEING;

EID: 38149099226     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I07-153     Document Type: Article

References (24)

1. World Health Organization. Magnitude and causes of visual impairment. Fact sheet 282, November 2004. Available at: http://www.who.int/mediacentre/factsheets/fs282/en. Accessed January 9, 2007.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99(6):933-43.
3. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48(3):257-93.
4. Bonastre J, Le Pen C, Soubrane G, Quentel G. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003;21(3):181-90.
5. Hopley C, Carter R, Mitchell P. Measurement of the economic impact of visual impairment from age-related macular degeneration in Australia. Clin Experiment Ophthalmol 2003;31(6):522-9.
6. Hart PM, Chakravarthy U, Stevenson MR, Jamison JQ. A vision specific functional index for use in patients with age related macular degeneration. Br J Ophthalmol 1999;83(10):1115-20.
7. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116(4):514-20.
8. Chia EM, Wang JJ, Rochtchina E, Smith W, Cumming RR, Mitchell P. Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004;45(1):71-6.
9. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005;40(3):277-87.
10. Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. Pharmacoeconomics 2006;24(4):319-34.
11. Sharma S, Dugar A, Bakal J, Brown G, Shah G. Economic resources utilized in a cohort of patients with age-related macular degeneration (AMD). Value Health 2004;7(3):260.
12. Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005;40(3):369-77.
13. Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007;125(9):1249-54.
14. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD, for the NEI-VFQ Field Test Investigators. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol 1998; 116(11):1496-504.
15. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, for the National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119(7):1050-8.
16. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33(5):337-43.
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67(6):361-70.
18. Canadian Institute for Health Information. Analysis of 2003: 2003 data from the Canadian MIS Database (CMDB). Ottawa, Ont.: Canadian Institute for Health Information. Available at: http://secure.cihi.ca/cihiweb/dispPage.jsp? cw_page=spend_canmis_e. Accessed January 2, 2007.
19. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index. Toronto, Ont.: Ontario Ministry of Health and Long-Term Care. No. 38, January 30, 2003. Available at: http://www.health. gov.on.ca/english/providers/program/drugs/formulary/ed38_0_bk.pdf. Accessed December 18, 2006.
20. Miskala PH, Hawkins BS, Mangione CM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization - SST Report No. 1. Arch Ophthalmol 2003;121(4):531-9.
21. Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 2005;46(11):4016-23.
22. Ivers RQ, Norton R, Cumming RG, Butler M, Campbell AJ. Visual impairment and risk of hip fracture. Am J Epidemiol 2000;152(7):633-9.
23. Legood R, Scuffham P, Cryer C. Are we blind to injuries in the visually impaired? A review of the literature. Inj Prev 2002;8(2):155-60.
24. Eichenbaum JW, Burton WB, Eichenbaum GM, Mulvihill M. The prevalence of eye disease in nursing home and non-nursing home geriatric populations. Arch Gerontol Geriatr 1999; 28(3):191-204.